Kawaguchi Makiko, Banno Kouji, Susumu Nobuyuki, Yanokura Megumi, Kuwabara Yoshiko, Hirao Nobumaru, Tsukazaki Katsumi, Nozawa Shiro
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Anticancer Res. 2005 Sep-Oct;25(5):3547-51.
In vitro anticancer drug sensitivity tests have been performed for various types of cancers, and a relationship with clinical response has been observed. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) is a new in vitro anticancer drug sensitivity test by Yabushita et al., recently reported to be useful in ovarian cancer. CD-DST allows analysis of a small number of cells, compared to other anticancer drug sensitivity tests. Here, we report a successful analysis of anticancer drug sensitivity by CD-DST using cancerous ascites and pleural fluid samples from 2 patients with advanced ovarian cancer. To our knowledge, this is only the second report of the application of CD-DST in ovarian cancer, and our results suggest that CD-DST could be helpful in the selection of anticancer drugs for neoadjuvant chemotherapy in advanced ovarian cancer.
已针对各种类型的癌症进行了体外抗癌药物敏感性测试,并观察到了其与临床反应的关系。胶原凝胶微滴包埋培养药物敏感性测试(CD-DST)是由Yabushita等人提出的一种新的体外抗癌药物敏感性测试,最近报道其在卵巢癌中有用。与其他抗癌药物敏感性测试相比,CD-DST能够分析少量细胞。在此,我们报告了使用2例晚期卵巢癌患者的癌性腹水和胸水样本通过CD-DST成功分析抗癌药物敏感性的情况。据我们所知,这是CD-DST应用于卵巢癌的第二篇报道,我们的结果表明CD-DST有助于晚期卵巢癌新辅助化疗中抗癌药物的选择。